G9a inhibitors and ezh2 inhibitors as multifaceted covid-19 therapeutics
AssigneeThe University of North Carolina at Chapel Hill
InventorXian Chen
Life of this patent
Estimating the term…
Abstract
Method of treating subjects suffering from symptoms related to a coronavirus infection, including COVID-19 viral infections, are provided. The methods include administering to a subject an inhibitor of G9a, an inhibitor of Ezh2, or combinations of the two. Such inhibitors can be small molecule inhibitors, including for example UNC0642 and UNCI 999. Methods of blocking G9a translational regulation of inflammation in a subject are also provided. Additionally, methods of identifying a compound to treat and/or prevent chronic and/or acute inflammation in a subject, based on identifying compound that block G9a translational regulation, are provided.
Claims33
A method of treating a subject suffering from symptoms related to a coronavirus infection and/or COVID-19, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and/or combinations thereof.
A method of blocking G9a translational regulation of hyperinflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of G9a, wherein G9a translational regulation of inflammation in the subject is blocked or substantially reduced.
A method of identifying a compound to treat and/or prevent chronic and/or hyperinflammation in a subject, the method comprising identifying a compound that blocks G9a translational regulation of inflammation in the subject.
Use of a composition for treating a subject suffering from symptoms related to a coronavirus infection, comprising administering to the subject the composition comprising a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and/or combinations thereof.
Dependencies are inferred from the claim text.